Monte Rosa Therapeutics, Inc. GLUE Gain (Loss), Foreign Currency Transaction, before Tax
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s gain (loss), foreign currency transaction, before tax?
- Monte Rosa Therapeutics, Inc. (GLUE) reported gain (loss), foreign currency transaction, before tax of -$8K in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s gain (loss), foreign currency transaction, before tax changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s gain (loss), foreign currency transaction, before tax decreased by 104.6% year-over-year, from $173K to -$8K.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s gain (loss), foreign currency transaction, before tax?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s gain (loss), foreign currency transaction, before tax has grown at a 111.6% compound annual growth rate (CAGR), from -$162K to $1.53M.